Dow, S&P 500, Nasdaq futures edge higher as hopes for an Iran deal grow

💻 Marvell stock hits record high after Nvidia’s $2 billion move and Amazon AI chip push

Marvell Technology shares climbed to new records Monday, building on Friday’s surge as Nvidia’s $2 billion bet fueled optimism around Marvell’s role in Amazon’s AI chip plans.

The stock traded up roughly 2.1% at $131.22 by late morning, after reaching $135.18. Nvidia, meanwhile, hovered near flat.

This shift is significant: AI investments are spilling over from Nvidia’s GPUs to broader data center infrastructure.

Marvell’s business centers on application-specific integrated circuits, or ASICs, chips tailored for certain jobs, and optical interconnect hardware, which pushes data between servers and racks using light.

That approach speeds things up and cuts power needs. TechStock² reports.


🧬 Hoth Therapeutics soars in pre-market after fat burning study

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease.

"HT-VA represents a major milestone for Hoth as we expand into high-value metabolic indications," said Robb Knie, Chief Executive Officer of Hoth Therapeutics.

"These results demonstrate that GDNF is not simply reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists." PR Newswire reports.


💻 Sandisk and Oracle shares soar on Nasdaq inclusion and AI launch; Conagra CEO exit drag stocks

Sandisk Corp. shares jumped 11.8% as it prepares to join the Nasdaq 100 Index on April 20, 2026. Oracle Corp. surged 12.7% after unveiling its AI-driven Oracle Utilities Opower platform, signaling strong investor interest in technology innovations.

Allogene Therapeutics climbed 12.5%, buoyed by positive phase 2 trial results for its blood cancer therapy.

Conversely, Conagra Brands shares fell 4.4% following the announcement of CEO Sean Connolly's planned departure effective May 31.

These moves highlight shifting investor focus amid leadership changes and AI developments impacting stock trajectories. TechStock² reports.


💻 AI arms race triggers $143 billion explosion in chip gear spending

Wafer fab equipment (WFE) spending continued its upward trajectory in 2025, underscoring the semiconductor industry's shift toward AI-led growth and advanced manufacturing.

Global WFE vendor revenue rose 12% year over year to $143 billion in 2025, driven by large-scale AI infrastructure build-outs.

Demand surged for leading-edge logic, high-bandwidth memory (HBM), and advanced packaging tools.

According to Counterpoint Research's Wafer Fab Equipment Tracker, the top five manufacturers posted a combined 14% revenue increase to $114 billion, supported by double-digit growth in both systems and services. Benzinga reports.


💊 Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said on Tuesday it is partnering with OpenAI to deploy artificial intelligence across its business, from drug discovery to manufacturing and commercial operations.

The maker of Wegovy and Ozempic said the partnership would use OpenAI's technology to analyse complex datasets, identify promising drug candidates and improve efficiency in manufacturing, supply chains, distribution and corporate operations.

Drugmakers are increasingly using AI to streamline the more tedious parts of drug development, from finding clinical trial participants and selecting sites to preparing regulatory filings, though industry executives say the technology has not yet fully delivered on the harder task of discovering major new molecules. Reuters reports.

Time (ET)/ Report/ Period

6:00 AM - NFIB optimism index - March
8:30 AM - Producer price index - March
8:30 AM - Core PPI - March

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.